These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 7615809)

  • 1. The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukin-1 soluble receptor.
    Burger D; Chicheportiche R; Giri JG; Dayer JM
    J Clin Invest; 1995 Jul; 96(1):38-41. PubMed ID: 7615809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of osteoclast-activating factor activity of multiple myeloma bone marrow cells by different interleukin-1 inhibitors.
    Torcia M; Lucibello M; Vannier E; Fabiani S; Miliani A; Guidi G; Spada O; Dower SK; Sims JE; Shaw AR; Dinarello CA; Garaci E; Cozzolino F
    Exp Hematol; 1996 Jul; 24(8):868-74. PubMed ID: 8690044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An interleukin 1 receptor antagonist blocks the IL-1-induced IL-6 paracrine production through a prostaglandin E2-related mechanism in multiple myeloma.
    Lu ZY; Bataille R; Poubelle P; Rapp MJ; Harousseau JL; Klein B
    Stem Cells; 1995 Aug; 13 Suppl 2():28-34. PubMed ID: 8520508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of granuloma formation induced by potassium permanganate in the mouse by a specific human recombinant receptor antagonist for interleukin-1 (hrIL-1ra).
    Conti P; Panara MR; Fridas S; Barbacane RC; Grilli A; Placido FC; Reale M; Fiore S
    Cell Immunol; 1993 Apr; 147(2):446-57. PubMed ID: 8384086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural and recombinant human IL-1 receptor antagonists block the effects of IL-1 on bone resorption and prostaglandin production.
    Seckinger P; Klein-Nulend J; Alander C; Thompson RC; Dayer JM; Raisz LG
    J Immunol; 1990 Dec; 145(12):4181-4. PubMed ID: 2147937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipopolysaccharide induces human interleukin-1 receptor antagonist and interleukin-1 production in the same cell.
    Andersson J; Björk L; Dinarello CA; Towbin H; Andersson U
    Eur J Immunol; 1992 Oct; 22(10):2617-23. PubMed ID: 1396967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the suppressive effects of interleukin-10 and interleukin-4 on synovial fluid macrophages and blood monocytes from patients with inflammatory arthritis.
    Hart PH; Ahern MJ; Smith MD; Finlay-Jones JJ
    Immunology; 1995 Apr; 84(4):536-42. PubMed ID: 7790026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The interleukin-1 receptor antagonist and its delivery by gene transfer.
    Evans CH; Robbins PD
    Receptor; 1994; 4(1):9-15. PubMed ID: 8038709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential binding of human interleukin-1 (IL-1) receptor antagonist to natural and recombinant soluble and cellular IL-1 type I receptors.
    Svenson M; Nedergaard S; Heegaard PM; Whisenand TD; Arend WP; Bendtzen K
    Eur J Immunol; 1995 Oct; 25(10):2842-50. PubMed ID: 7589081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Binding of IL-1 alpha, IL-1 beta, and IL-1 receptor antagonist by soluble IL-1 receptors and levels of soluble IL-1 receptors in synovial fluids.
    Arend WP; Malyak M; Smith MF; Whisenand TD; Slack JL; Sims JE; Giri JG; Dower SK
    J Immunol; 1994 Nov; 153(10):4766-74. PubMed ID: 7963543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of prostaglandin H synthase-2 and tumor necrosis factor-alpha in human amnionic WISH cells by various stimuli occurs through distinct intracellular mechanisms.
    Hulkower KI; Otis ER; Li J; Ennis BW; Cugier DJ; Bell RL; Carter GW; Glaser KB
    J Pharmacol Exp Ther; 1997 Feb; 280(2):1065-74. PubMed ID: 9023325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An interleukin 1 inhibitor affects both cell-associated interleukin 1-induced T cell proliferation and PGE2/collagenase production by human dermal fibroblasts and synovial cells.
    Seckinger P; Kaufmann MT; Dayer JM
    Immunobiology; 1990 Jun; 180(4-5):316-27. PubMed ID: 2168857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis of metalloproteases and interleukin 6 (IL-6) in human osteoarthritic synovial membrane is an IL-1 mediated process.
    Pelletier JP; McCollum R; Cloutier JM; Martel-Pelletier J
    J Rheumatol Suppl; 1995 Feb; 43():109-14. PubMed ID: 7752112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opposite effects of interleukin-13 and interleukin-12 on the release of inflammatory cytokines, cytokine inhibitors and prostaglandin E from synovial fibroblasts and blood mononuclear cells.
    Seitz M; Loetscher P; Dewald B; Towbin H; Baggiolini M
    Eur J Immunol; 1996 Sep; 26(9):2198-2202. PubMed ID: 8814267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin 13 suppresses cytokine production and stimulates the production of 15-HETE in PBMC. A comparison between IL-4 and IL-13.
    Deleuran B; Iversen L; Deleuran M; Yssel H; Kragballe K; Stengaard-Pedersen K; Thestrup-Pedersen K
    Cytokine; 1995 May; 7(4):319-24. PubMed ID: 8589261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV predominantly induces IL-1 receptor antagonist over IL-1 synthesis in human primary monocytes.
    Zavala F; Rimaniol AC; Boussin F; Dormont D; Bach JF; Descamps-Latscha B
    J Immunol; 1995 Sep; 155(5):2784-93. PubMed ID: 7650404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitory activity of IL-1 receptor antagonist depends on the balance between binding capacity for IL-1 receptor type 1 and IL-1 receptor type II.
    Ruggiero P; Bossù P; Macchia G; Del Grosso E; Sabbatini V; Bertini R; Colagrande A; Bizzarri C; Maurizi G; Di Cioccio V; D'Andrea G; Di Giulio A; Frigerio F; Grifantini R; Grandi G; Tagliabue A; Boraschi D
    J Immunol; 1997 Apr; 158(8):3881-7. PubMed ID: 9103457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of expression of IL-1 receptor antagonist protein in human synovial and dermal fibroblasts.
    Krzesicki RF; Hatfield CA; Bienkowski MJ; McGuire JC; Winterrowd GE; Chapman DL; Berger AE; McEwan RN; Carter DB; Chosay JG
    J Immunol; 1993 May; 150(9):4008-18. PubMed ID: 8473746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of type II nitric oxide synthase in primary human astrocytes and microglia: role of IL-1beta and IL-1 receptor antagonist.
    Liu J; Zhao ML; Brosnan CF; Lee SC
    J Immunol; 1996 Oct; 157(8):3569-76. PubMed ID: 8871657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p55 and p75 tumor necrosis factor receptors are expressed and mediate common functions in synovial fibroblasts and other fibroblasts.
    Butler DM; Feldmann M; Di Padova F; Brennan FM
    Eur Cytokine Netw; 1994; 5(5):441-8. PubMed ID: 7880974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.